Auven Therapeutics Mergers and Acquisitions Summary

Auven Therapeutics’ most common sector for investment is life science (100%). The Firm’s most common investment types include buyout (lbo, mbo, mbi) (50%) and venture (50%). In total, Auven Therapeutics has invested in 1 US state and 2 different countries.

The Firm’s most common exit type is trade sale (100%). Auven Therapeutics’ largest (disclosed) exit occurred in 2013 when it sold Spirogen for $240M.

Join Mergr to view Auven Therapeutics’ full profile and discover more small private equity firms just like it.

Auven Therapeutics


Auven Therapeutics is a private equity firm focused on investing in life science companies. Auven looks to acquire controlling ownership in promising therapeutic products or platforms and develop programs to selling them as clinically and commercially validated products to established pharmaceutical companies. Auven was established in 2007 and is headquartered in St. Thomas, US Virgin Islands.

M&A Summary

Buy vs Sell

Top M&A Advisors

Join Mergr to view the latest updates and news from Auven Therapeutics.

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
  • 3.8K Private Equity Firms
  • 134K M&A Transactions
  • 143K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.0K M&A Advisors
    (Investment Banks and Law Firms)
  • 37K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.